Evidence map›Paper›PMID 42440705›Full record

Trial reportFrontiers in medicine2026

A multi-mineral intervention is associated with improved intestinal permeability in patients with ulcerative colitis: results from a pilot trial.

Muhammad N Aslam, Danielle Kim Turgeon, Shannon McClintock, Ron Allen, Ananda Sen, James Varani

2 registry-linked trialsAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03869905 phase2active not recruitingnot on this map

Aquamin®, a Multi-mineral Natural Product From Red Marine Algae, as an Adjuvant Intervention for Mild Ulcerative Colitis and Ulcerative Colitis in Remission

TypeinterventionalSponsorMuhammad N Aslam, MDRan2019 to 2027Enrolled40ConditionsUlcerative ColitisArmsAquamin®, Placebo first then Aquamin®
NCT04855799 phase2completednot on this map

Direct Measurement of Gastrointestinal Permeability Change in Response to Aquamin®

TypeinterventionalSponsorJames VaraniRan2021 to 2024Enrolled35ConditionsUlcerative Colitis, Healthy, Irritable Bowel Syndrome With DiarrheaArmsAquamin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Muhammad N AslamDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Danielle Kim TurgeonDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Shannon McClintockDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Ron AllenDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Ananda SenDepartment of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
James VaraniDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Previous studies have shown that Aquamin Methods: Subjects with mild ulcerative colitis (UC) or UC in remission and healthy controls were enrolled in an open-label, pilot-phase trial and received Aquamin Results: In this pilot study (NCT04855799), which included UC patients and healthy controls ( Conclusion: Results from this exploratory study provide preliminary evidence that Aquamin Clinical trial registration: https://clinicaltrials.gov/study/NCT04855799, identifier NCT04855799.

Indexed as

Aquamingut barrierinflammatory bowel diseaseintestinal permeabilitymineralstrace elementsulcerative colitis

Identifiers

PMID42440705
PMCPMC13333513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.